Literature DB >> 26565004

Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012-2013.

Joshua G Petrie1, Caroline Cheng1, Ryan E Malosh1, Jeffrey J VanWormer2, Brendan Flannery3, Richard K Zimmerman4, Manjusha Gaglani5, Michael L Jackson6, Jennifer P King2, Mary Patricia Nowalk4, Joyce Benoit6, Anne Robertson5, Swathi N Thaker3, Arnold S Monto1, Suzanne E Ohmit1.   

Abstract

BACKGROUND: Influenza causes significant morbidity and mortality, with considerable economic costs, including lost work productivity. Influenza vaccines may reduce the economic burden through primary prevention of influenza and reduction in illness severity.
METHODS: We examined illness severity and work productivity loss among working adults with medically attended acute respiratory illnesses and compared outcomes for subjects with and without laboratory-confirmed influenza and by influenza vaccination status among subjects with influenza during the 2012-2013 influenza season.
RESULTS: Illnesses laboratory-confirmed as influenza (ie, cases) were subjectively assessed as more severe than illnesses not caused by influenza (ie, noncases) based on multiple measures, including current health status at study enrollment (≤7 days from illness onset) and current activity and sleep quality status relative to usual. Influenza cases reported missing 45% more work hours (20.5 vs 15.0; P < .001) than noncases and subjectively assessed their work productivity as impeded to a greater degree (6.0 vs 5.4; P < .001). Current health status and current activity relative to usual were subjectively assessed as modestly but significantly better for vaccinated cases compared with unvaccinated cases; however, no significant modifications of sleep quality, missed work hours, or work productivity loss were noted for vaccinated subjects.
CONCLUSIONS: Influenza illnesses were more severe and resulted in more missed work hours and productivity loss than illnesses not confirmed as influenza. Modest reductions in illness severity for vaccinated cases were observed. These findings highlight the burden of influenza illnesses and illustrate the importance of laboratory confirmation of influenza outcomes in evaluations of vaccine effectiveness.
© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  illness severity; medically attended acute respiratory illness; medically attended influenza; vaccine effectiveness; work productivity

Mesh:

Substances:

Year:  2015        PMID: 26565004      PMCID: PMC4725387          DOI: 10.1093/cid/civ952

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

1.  The validity and reproducibility of a work productivity and activity impairment instrument.

Authors:  M C Reilly; A S Zbrozek; E M Dukes
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

2.  'Choosing' to work when sick: workplace presenteeism.

Authors:  Kevin Dew; Vera Keefe; Keitha Small
Journal:  Soc Sci Med       Date:  2004-12-07       Impact factor: 4.634

3.  Evaluation of influenza vaccination in health-care workers, using rapid antigen detection test.

Authors:  Yoichiro Ito; Hanako Sumi; Toshihiko Kato
Journal:  J Infect Chemother       Date:  2006-04       Impact factor: 2.211

4.  The annual impact of seasonal influenza in the US: measuring disease burden and costs.

Authors:  Noelle-Angelique M Molinari; Ismael R Ortega-Sanchez; Mark L Messonnier; William W Thompson; Pascale M Wortley; Eric Weintraub; Carolyn B Bridges
Journal:  Vaccine       Date:  2007-04-20       Impact factor: 3.641

5.  Influenza-associated hospitalizations in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Carolyn B Bridges; Nancy J Cox; Keiji Fukuda
Journal:  JAMA       Date:  2004-09-15       Impact factor: 56.272

6.  Does subjective social status predict health and change in health status better than objective status?

Authors:  Archana Singh-Manoux; Michael G Marmot; Nancy E Adler
Journal:  Psychosom Med       Date:  2005 Nov-Dec       Impact factor: 4.312

7.  Frequency of acute respiratory illnesses and circulation of respiratory viruses in households with children over 3 surveillance seasons.

Authors:  Arnold S Monto; Ryan E Malosh; Joshua G Petrie; Mark G Thompson; Suzanne E Ohmit
Journal:  J Infect Dis       Date:  2014-06-06       Impact factor: 5.226

8.  Viruses associated with acute respiratory infections and influenza-like illness among outpatients from the Influenza Incidence Surveillance Project, 2010-2011.

Authors:  Ashley Fowlkes; Andrea Giorgi; Dean Erdman; Jon Temte; Kate Goodin; Steve Di Lonardo; Yumei Sun; Karen Martin; Michelle Feist; Rachel Linz; Rachelle Boulton; Elizabeth Bancroft; Lisa McHugh; Jose Lojo; Kimberly Filbert; Lyn Finelli
Journal:  J Infect Dis       Date:  2013-12-12       Impact factor: 5.226

9.  Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses.

Authors:  Danuta M Skowronski; Naveed Z Janjua; Gaston De Serres; Suzana Sabaiduc; Alireza Eshaghi; James A Dickinson; Kevin Fonseca; Anne-Luise Winter; Jonathan B Gubbay; Mel Krajden; Martin Petric; Hugues Charest; Nathalie Bastien; Trijntje L Kwindt; Salaheddin M Mahmud; Paul Van Caeseele; Yan Li
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

10.  A cross-sectional analysis of symptom severity in adults with influenza and other acute respiratory illness in the outpatient setting.

Authors:  Jeffrey J VanWormer; Maria E Sundaram; Jennifer K Meece; Edward A Belongia
Journal:  BMC Infect Dis       Date:  2014-05-01       Impact factor: 3.090

View more
  15 in total

1.  Respiratory syncytial virus hospitalization in middle-aged and older adults.

Authors:  Ryan E Malosh; Emily T Martin; Amy P Callear; Joshua G Petrie; Adam S Lauring; Lois Lamerato; Alicia M Fry; Jill Ferdinands; Brendan Flannery; Arnold S Monto
Journal:  J Clin Virol       Date:  2017-09-07       Impact factor: 3.168

2.  Repeated influenza vaccination for preventing severe and fatal influenza infection in older adults: a multicentre case-control study.

Authors:  Itziar Casado; Ángela Domínguez; Diana Toledo; Judith Chamorro; Jenaro Astray; Mikel Egurrola; María Amelia Fernández-Sierra; Vicente Martín; María Morales-Suárez-Varela; Pere Godoy; Jesús Castilla
Journal:  CMAJ       Date:  2018-01-08       Impact factor: 8.262

3.  Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness.

Authors:  Ana E Gamiño-Arroyo; M Lourdes Guerrero; Sean McCarthy; Alejandra Ramírez-Venegas; Beatriz Llamosas-Gallardo; Arturo Galindo-Fraga; Sarbelio Moreno-Espinosa; Yuri Roldán-Aragón; Javier Araujo-Meléndez; Sally Hunsberger; Violeta Ibarra-González; Julia Martínez-López; Luis A García-Andrade; Heather Kapushoc; H Preston Holley; Mary C Smolskis; Guillermo M Ruiz-Palacios; John H Beigel
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

4.  Prevalence and Predictors of Persistent Symptoms After Clearance of SARS-CoV-2 Infection: A Multicenter Study from Egypt.

Authors:  Marwa Khalaf; Mohamed Alboraie; Muhammad Abdel-Gawad; Mohamed Abdelmalek; Ahmed Abu-Elfatth; Walaa Abdelhamed; Mariam Zaghloul; Rabab ElDeeb; Doaa Abdeltwab; Mohamed Abdelghani; Fathiya El-Raey; Hani Aboalam; Azza Badry; Mina Tharwat; Shima Afify; Doaa Elwazzan; Ahmed Shawkat Abdelmohsen; Hayam Fathy; Shaker Wagih Shaltout; Helal F Hetta; Shamardan E Bazeed
Journal:  Infect Drug Resist       Date:  2022-05-20       Impact factor: 4.177

5.  Influenza A virus-induced host caspase and viral PA-X antagonize the antiviral host factor, histone deacetylase 4.

Authors:  Henry D Galvin; Matloob Husain
Journal:  J Biol Chem       Date:  2019-11-22       Impact factor: 5.157

6.  Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections.

Authors:  Pranab K Mukherjee; Frank Esper; Ken Buchheit; Karen Arters; Ina Adkins; Mahmoud A Ghannoum; Robert A Salata
Journal:  BMC Infect Dis       Date:  2017-01-14       Impact factor: 3.090

7.  Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults.

Authors:  L Coughlan; S Sridhar; R Payne; M Edmans; A Milicic; N Venkatraman; B Lugonja; L Clifton; C Qi; P M Folegatti; A M Lawrie; R Roberts; H de Graaf; P Sukhtankar; S N Faust; D J M Lewis; T Lambe; Avs Hill; S C Gilbert
Journal:  EBioMedicine       Date:  2018-02-15       Impact factor: 8.143

Review 8.  The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 infection.

Authors:  Narges Moghimi; Mario Di Napoli; José Biller; James E Siegler; Rahul Shekhar; Louise D McCullough; Michelle S Harkins; Emily Hong; Danielle A Alaouieh; Gelsomina Mansueto; Afshin A Divani
Journal:  Curr Neurol Neurosci Rep       Date:  2021-06-28       Impact factor: 5.081

9.  Host-directed combinatorial RNAi improves inhibition of diverse strains of influenza A virus in human respiratory epithelial cells.

Authors:  Michael A Estrin; Islam T M Hussein; Wendy B Puryear; Anne C Kuan; Stephen C Artim; Jonathan A Runstadler
Journal:  PLoS One       Date:  2018-05-18       Impact factor: 3.240

10.  Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020.

Authors:  Mark W Tenforde; Sara S Kim; Christopher J Lindsell; Erica Billig Rose; Nathan I Shapiro; D Clark Files; Kevin W Gibbs; Heidi L Erickson; Jay S Steingrub; Howard A Smithline; Michelle N Gong; Michael S Aboodi; Matthew C Exline; Daniel J Henning; Jennifer G Wilson; Akram Khan; Nida Qadir; Samuel M Brown; Ithan D Peltan; Todd W Rice; David N Hager; Adit A Ginde; William B Stubblefield; Manish M Patel; Wesley H Self; Leora R Feldstein
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-07-31       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.